AcelRx Pharmaceuticals (ACRX) Posts Q3 Loss of 30c/Share

AcelRx Pharmaceuticals (NASDAQ: ACRX) reported Q3 EPS of ($0.30), $0.04 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $408 thousand versus the consensus estimate of $80 thousand.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Science Applications Int'l (SAIC) Tops Q2 EPS by 70c
• Lucky Strike Entertainment Corporation (LUCK) reported Q2 Revenue ; Offers Guidance
• Elastic N.V. (ESTC) Tops Q1 EPS by 12c, Beats on Revenue; offers FY27 Guidance